Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioMark Diagnostics Inc C.BUX

Alternate Symbol(s):  BMKDF

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring... see more

Recent & Breaking News (CSE:BUX)

BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting

Newsfile June 5, 2023

BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay

Newsfile May 31, 2023

BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

Newsfile May 3, 2023

Advancing new methods to detect rare tumors early

Jonathon Brown March 17, 2023

BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors

Newsfile March 16, 2023

BioMark Provides Third Quarter Operational Update and 2023 Outlook

Newsfile March 1, 2023

Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring

Newsfile February 7, 2023

BioMark (CSE:BUX) updates on lung cancer liquid biopsy trials

Caroline Egan  January 11, 2023

BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch

Newsfile January 11, 2023

BioMark Provides Business Update and Second Quarter Financial Results

Newsfile November 28, 2022

BioMark's (CSE: BUX) glioblastoma study demonstrates inhibiting cancer cells

Sabrina Cuthbert October 27, 2022

BioMark's Glioblastoma Study Published in Cancers Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and Chemotherapy

Newsfile October 27, 2022

The US Patent Office Grants BioMark Additional Patent for Its Liquid Biopsy Technology

Newsfile September 20, 2022

BioMark (CSE:BUX) to present validation data of its multianalyte metabolite panel for lung cancer screening at the ESMO Congress 2022

Azuka Onwuka September 8, 2022

BioMark to Present Validation Data of Its Multianalyte Metabolite Panel for Lung Cancer Screening at the ESMO Congress 2022

Newsfile September 8, 2022

BioMark Selected by the Medical Alley and Investissement Quebec to Join the Us Go-To-Market Accelerator

Newsfile September 1, 2022

BioMark Provides First-Quarter 2022 Financial Results and Operational Update

Newsfile August 30, 2022

BioMark Provides Financial Results for the Year Ended March 31, 2022, and Recent Corporate Highlights

Newsfile July 14, 2022

BioMark Continues to Strengthen Its Intellectual Property Position with New Patent and Trademark Use in Canada

Newsfile June 21, 2022

BioMark Diagnostics (CSE:BUX) and the Icahn School of Medicine announce partnership on lung cancer screening

Azuka Onwuka June 7, 2022